Remsleep Holdings INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OTC.Pink
REMSleep Holdings reports a significant net loss for 2025 while transitioning to its new DeltaWave CPAP product line.
OTC.Pink
REMSleep Holdings, Inc. reports a net loss for 2024 but recognizes revenue from ResPlus CPAP system sales and continues development of its DeltaWave product.
OTC.Pink
REMSleep Holdings reports a net loss of $1.78 million for 2023 and acknowledges substantial doubt about its ability to continue as a going concern.